| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-13-2024 | 06-30-2024 | 10-Q | |
| 2 | 05-13-2024 | 03-31-2024 | 10-Q | |
| 3 | 04-01-2024 | 12-31-2023 | 10-K | |
| 4 | 11-13-2023 | 09-30-2023 | 10-Q | |
| 5 | 09-15-2023 | 06-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The company has submitted a request for a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration...
Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced that it has selected neuropathic pain as the primary indication for it...
https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08262024_MIRA_Sorensen.pdf
MIRA Pharmaceuticals stock surges on promising preclinical results of oral ketamine analog, Ketamir-2, showing 100% pain thresh...
- SEC Filing
MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical c...
